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Abstract
Objectives. RA and its medication, especially TNF-a inhibitors, increase the risk of clinical tuberculo-
sis (TB) infection. We aimed to investigate the clinical manifestations, incidence and temporal changes
in TB occurring concurrently with rheumatic diseases (RDs) between 1995 and 2007.
Methods. We combined the register of the Social Insurance Institution of Finland and the National
Infectious Disease Register to find adult patients with reimbursed DMARDs and with a TB notification
between 1995 and 2007. After reviewing the medical records, we described their clinical manifestations
and medications, explored TB incidence trends using Poisson regression, and compared the incidence
of TB with that of the general population.
Results. We identified 291 patients with both TB and rheumatic disease (RD), 196 of whom had RA.
Between 1995 and 2007, the incidence of TB in adult RD decreased from 58.8 to 30.0 per 100 000
(trend P < 0.001, average marginal effect 3.4/100 000 per year, 95% CI 4.4, 2.4). Compared with
the general population, the incidence was 4-fold. Among RD patients, pulmonary TB was the most
common form of TB (72.6%). Disseminated TB was present in 56 (19.6%) patients.
Conclusion. The incidence of TB among RD patients was 4-fold that of the general population,
and it declined between 1995 and 2007. Disseminated TB was present in nearly 20% of patients.
Key words: rheumatoid arthritis, rheumatic disease, tuberculosis incidence, tumour necrosis factor inhibitors,
latent tuberculosis, pulmonary tuberculosis, disseminated tuberculosis, DMARDs
Introduction
In Finland, the annual incidence rate of RA is 45/
100 000, and its prevalence in the adult population is
0.8% [1, 2]. RA and its medication, especially TNF-a
inhibitors (TNFi), increase the risk of active tuberculosis
(TB) infection [3–5]. In Korea, a country with a high inci-
dence of TB, the risk of TB between 2001 and 2005
was 8.9 times as high for patients with RA as for the
general population and 30.1 times as high for RA
patients treated with infliximab [6]. Reactivation of latent
tuberculosis infection (LTBI) during TNFi treatment was
first reported in 2001 and is now well documented [7–9].
This risk can be reduced by routine screening and
treatment of LTBI at the start of immunosuppressive
treatment [9, 10]. The national Finnish guidelines for
screening and treating LTBI in RA patients were pub-
lished in 2004 [11].
Key messages
. The incidence of tuberculosis among rheumatic disease patients halved between 1995 and 2007 in Finland.
. Compared with that of the general population, the incidence of tuberculosis among rheumatic disease
patients was 4-fold.
. Disseminated and extra-pulmonary forms of tuberculosis appeared in up to 46.5% of rheumatic disease patients.
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Besides RA medication, the increased risk of TB in RA
patients may also be related to immunological disturban-
ces associated with the disease, to genetic components,
co-morbidities and frailty induced by the disease and
medications [12–16]. A study from Sweden (a country
with a low incidence of TB) found that compared with the
general population, even RA patients not exposed to bio-
logics had a 4-fold increased risk of TB [17]. Owing to
the previous high incidence of TB in Finland, those born
in Finland before 1950 have had a high likelihood of
exposure to TB in childhood [18]. In 2001, Finland be-
came a low-incidence country, with a TB incidence below
10/100 000 [19]. The incidence of TB in RA and rheu-
matic diseases (RDs) in Finland is as yet unknown.
During TNFi treatment, TB in RA patients is often dis-
seminated or extra-pulmonary [7, 8, 20], but clinical mani-
festations of TB during treatment with synthetic DMARDs
(sDMARDs) or in rheumatic disease (RD) patients without
specific medication remain poorly documented.
We created a nationwide retrospective register study,
with detailed individual data for patients who developed
active TB between 1995 and 2007, to explore the inci-
dence of TB in RA and in other RDs. Between 2001 and
2007, several TNFi became available and gradually be-
came more generally used. We thus sought clinically rel-




We combined two nationwide data sources. The register
of the Social Insurance Institution of Finland lists people
with reimbursed DMARDs since 1966. The national
health insurance scheme covers the entire population of
Finland, which was 5.28 million in 2007 [21]. Eligibility
requires a comprehensive medical certificate written by
the attending physician and approved by an expert ad-
viser. All connective-tissue diseases, RA and compara-
ble diseases are grouped under one reimbursement
code in the Social Insurance Institution of Finland popu-
lation register. The reimbursement finishes if the person
dies or stays abroad for >1 year.
All mycobacterium diagnostics requiring cultures are
performed in the Tuberculosis Laboratory of the National
Institute for Health and Welfare (THL), which notifies the
National Infectious Disease Register (NIDR) in the case
of a new finding of Mycobacterium tuberculosis.
Between 1995 and 2006, physicians also had to notify
the NIDR about a positive culture, histologically con-
firmed cases of TB and sputum smear-positive pulmo-
nary TB. As of 2007, the statistics have also included
clinically diagnosed cases.
The patients were identified by cross-referencing
these two national registers. The Social Insurance
Institution of Finland provided data on adult patients
with reimbursed DMARDs between 1966 and 2007, and
the NIDR provided data on adult patients with a TB
notification between 1995 and 2007. The number receiv-
ing yearly reimbursement for DMARDs came from the
register of the Social Insurance Institution. The TB
incidence of the general population came from NIDR
data on adult patients with a TB notification.
Variables and case identification
We accessed individual social security numbers, the
date of the TB notification and the hospital where the
clinical samples were obtained or where the notification
was made. An internal medicine and infectious disease
specialist reviewed the original individual medical
records. After confirming RD and TB diagnoses, patients
with an RD and TB episode were identified as cases.
The TB diagnosis was accepted if it was bacteriologi-
cally confirmed or, if clinically diagnosed, the case had
histological or radiological evidence of TB, or the diag-
nosis was made differentially [22].
Additional recorded information about patients se-
lected as cases included smoking and drinking history,
detailed information on DMARD use, and co-morbidity
diagnoses and RD diagnoses, all based on the
International Classification of Diseases, 10th revision. If
the date of the RD diagnosis was unavailable, the date
recorded was when RD was first mentioned. We col-
lected TB exposure status, tuberculin skin test (TST)
positivity, radiological findings and details on the TB
infection.
The TST was considered positive if the induration was
over 5 mm or over 10 mm in Bacillus Calmette–Guérin-
vaccinated patients. Thorax X-rays or computed tomog-
raphy scans were examined if there was suspicion of
active intrathoracic TB, suspicion of a previous episode
of TB, or no suspicion of TB.
Tuberculosis was considered to be disseminated if
present in at least two non-contiguous organs.
Latent TB infection is defined by the World Health
Organization as a state of persistent immune response to
stimulation by M. tuberculosis antigens with no evidence of
clinically manifest active TB [23]. No gold standard exists
for diagnosing LTBI. During our study period, IFNc-
releasing assays (IGRAs) were not in clinical use in Finland.
We considered LTBI likely if the patient was born in a
high-incidence country, had a positive TST, had imaging
findings that indicated an earlier episode of TB, or had
known TB exposure or previously treated TB. The earlier
treatment was considered adequate according to the
Finnish contemporary guidelines if the patient had received
at least two effective anti-TB drugs for 12 (1950–1969) or
6 months (1970 and thereafter).
The outcome was assessed 6 months after discontinu-
ation of TB treatment. Treatment was determined to be
completed successfully if it lasted at least 6 months, and
by absence of failure. We recorded death before, during
or within 6 months after TB treatment. If TB was men-
tioned as a cause of death, death was determined as
the outcome.
The coordinating ethics committee of Helsinki and
Uusimaa Hospital District and the ethics committee of
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Carea (Kymenlaakso Social and Health Services) ap-
proved the study.
Statistical analysis
Summary statistics are presented as means or medians,
with S.D. or interquartile ranges (IQRs). To compare inde-
pendent samples for continuous variables, we used
Student’s unpaired t-test or the Wilcoxon rank sum test,
whichever was appropriate. For categorical variables,
we used the v2 test.
To investigate incidence trends, we used a Poisson
regression model. For the regression coefficient, we cal-
culated an average marginal effect that displays the av-
erage change in the annual incidence during the study
period. Data handling and statistical analyses were per-
formed with Microsoft Office and R (v.3.4.0, R
Foundation for Statistical Computing, Vienna, Austria).
Results
The register data linkage covering 988 049 patient-years
with reimbursed DMARDs yielded 388 individual patients
during 1995–2007, and of these, we accessed the medi-
cal records for 366 (94.3%). After reviewing their
medical records, we confirmed 291 as cases: 66
patients had no RD at the time of TB (diagnosis), but 31
of these received their RD diagnoses after a TB episode.
Eight patients had no TB, and in one patient TB was di-
agnosed in 1994. Of the 291 RD patients accepted who
had TB, in 251 (86.3%) TB was confirmed
bacteriologically. Of the 40 TB cases diagnosed clini-
cally, 33 (82.5%) were verified histologically, 4 (10%)
were treated because of radiological findings and 3 after
strong clinical suspicion of TB without another explana-
tion for their condition.
Patients
The basic data for the 291 patients are shown in
Table 1. Of these patients, 196 had RA, and 95 had an-
other RD. The various diagnoses of RD numbered >20,
with the largest sub-groups being polymyalgia rheuma-
tica (20%), AS (13.6%) and SLE (10.5%).
There were 127 seropositive RA patients (64.8% of
the RA cases). There were 182 RA patients with co-mor-
bidities (92.9%; mean number of co-morbidities three,
IQR two to five). Three patients had received immuno-
suppressive therapy for pulmonary disease, and one for
a renal transplant. Patients described as/known to be
TABLE 1. Characteristics of patients
Patient characteristics All RA Other RD
(n 5 291) (n 5 196) (n 5 95)
Age, mean (S.D.), range, years 70 (13), 15–93 71 (12), 17–92 68 (15), 15–93
Sex, n (%)
Male 105 (36) 69 (35) 36 (38)
Female 186 (64) 127 (65) 59 (62)
Disease duration, mean (S.D.), years 15 (13) 18 (13) 10 (11)
Smoking habits, n ¼ 187, n (%)
Non-smoker 65 (52) 37 (61)
Current smoker 27 (22) 15 (24)
Ex-smoker 33 (26) 9 (15)
Co-morbidities, n ¼ 289, n (%)
Pulmonary disease 57 (29) 22 (23)
Diabetes 25 (13) 16 (17)
Kidney disease 20 (10) 8 (8)
Medication for RD, n (%)
Glucocorticoids 123 (63) 57 (60)
sDMARDs 123 (63) 40 (42) P < 0.01
TNFi 21 (11) 4 (4)
Extra-articular RA manifestations, n (%)
Amyloidosis 15 (8)
Rheumatic pulmonary disease 15 (8)
Sicca syndrome 8 (4)
Felty’s syndrome 1 (0.5)
Other extra-articular manifestationa 21 (11)
The age, sex and duration of rheumatic disease of those with any RD who developed active TB in Finland during 1995–
2007 are shown. Smoking habits, common co-morbidities and RD medication at the time of diagnosis in RA patients and
in patients with RDs other than RA listed separately. The extra-articular disease manifestations of RA patients are listed.
aVasculitis, cutaneous manifestations, ceratitis, immune thrombocytopenia, Raynaud’s phenomenon, lymphangitis.
RD: rheumatic disease; sDMARDs: synthetic DMARDs; TB: tuberculosis; TNFi: TNF inhibitors.
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heavy users of alcohol numbered 15 (7.7%); eight
(4.1%) had an active malignancy. None had HIV
infection.
Of all 291 RD patients, 228 (78.4%) had received glu-
cocorticoids or any DMARDs at the time of TB diagno-
sis, 26 (8.9%) used or had used TNFi, and one patient
had previously used an IL-1 receptor antagonist
(anakinra).
Of those patients treated with bDMARDs, 19 (73.1%)
were screened for LTBI, 11 had at least one known TB
exposure, 4 a positive TST, and 4 suspicion of a previ-
ous episode of TB on thoracic X-ray. Only one had re-
ceived LTBI treatment.
Among the RD patients, at least one exposure to TB
was reported in 83 (28.5%), and 62 (74.7%) were
exposed to TB through active disease in one or more
relatives or household contacts. Of those patients aged
15–54 years, seven (21.2%) reported occupational expo-
sures, which is a significantly larger proportion than the
nine (3.5%) occupational exposures reported by those
 55 years (P < 0.001). No statistically significant
difference emerged between the reported number of TB
exposures between the oldest patients (66 years or
more) and the younger patients.
Incidence
Between 1995 and 2007, the incidence of TB in adult
RD patients with reimbursed DMARDs decreased from
58.8 to 30.0 per 100 000 (trend P < 0.001, average mar-
ginal effect 3.4/100 000 per year, 95% CI 4.4, 2.4;
Fig. 1). The incidence was 4-fold that of the general
population. Table 2 lists the mean numbers of annual
cases of TB in the patients whose medical records we
accessed.
Tuberculosis
The clinical picture of TB was known in 285 (97.9%)
cases; pulmonary TB was the most common form of TB
among RD patients (72.6%). We found 10 (3.5%) cases
of isolated TB pleurisy and found other extra-pulmonary
forms of TB in 68 (23.9%) patients. Disseminated TB
was present in 56 patients (19.6%). Figure 2 shows the
organ distribution of TB for RD patients treated or not
treated with bDMARDs.
A history of TB was identified for 36 RA patients. TST
was performed in 13 (36.1%) previously treated for TB:
5 (38.5%) were TST negative (3 of these without
DMARDs) and 8 (61.5%) were TST positive. Among the
previously treated RA patients, only four (11.1%) had re-
ceived adequate TB treatment. Of all 291 RD patients,
reactivation of their LTBI was the reason for infection in
279 cases (95.9%), and among RA patients in 189
(96.4%).
The mean time from symptom onset to TB diagnosis
was 16 weeks in all RA patients (median 9 weeks, IQR
4–20 weeks), and for previous and current bDMARD
users it was 12 weeks (median 11 weeks, IQR 7–
16 weeks). Seven patients lacked any subjective symp-
toms of TB, and 10 were diagnosed post-mortem.
One hundred and seven (58.5%) RA patients
completed their treatment successfully; 58 (31.7%) died.





















































Annual incidences (one per 100 000 person years) of
tuberculosis (TB) in Finland among the general popula-
tion as reported by the National Infectious Disease
Register (NIDR) were significantly lower (P < 0.01)
than incidences among patients with rheumatic disease
(RD). The incidence of both diminished during the study
period (P < 0.05).
TABLE 2. Mean yearly tuberculosis cases
Tuberculosis cases annually, mean (IQR) 1995–2000 2001–2007 1995–2007
RD 26.83 (22–29) 18.57 (15–20) 22.38 (15–28)
RD with bDMARDs 3.71 (2–6)
RD without bDMARDs 14.86 (12–15) 20.24 (14–28)
RA 17.50 (14–18) 13.00 (10–13) 15.08 (11–16)
RA with bDMARDs 3.14 (2–5)
RA without bDMARDs 9.86 (7–9) 13.38 (8–16)
The number of yearly tuberculosis cases with the IQR for time intervals 1995–2000 before bDMARDs, 2001–2007 after
bDMARDs came into clinical use, and for the whole study period. Numbers are for all RD patients and for RA patients
only.
bDMARDs: biological DMARDs; IQR: interquartile range; RD: rheumatic disease.












The annual incidence of TB in patients with RDs was
four times as high as in the general population. This re-
sult is consistent with an RA cohort study from Spain
(an intermediate-incidence country) and the studies from
Korea and Sweden [6, 17, 24]. During our study period,
the incidence of TB declined by almost 50%. This trend
is similar to that in the general population and can be
explained by an improved standard of living and by
strict TB control during the 20th century: a network of
TB hospitals, the TB Act 1948 and the Bacillus
Calmette–Guérin vaccine given to all children born in
hospitals as a part of the national vaccination pro-
gramme 1941–2006 [18, 19].
The declining TB incidence in RD patients despite in-
creasing clinical TNFi use reflects the cohort effect of
older generations with possible LTBI infection dying, but
it is evidence of effective LTBI screening and treatment
and of patient selection. Given that TNFi were expensive,
these were used first by young and working people.
The main reason for the higher incidence of TB in RD
patients is that both RDs and TB are more common in
the elderly, but RD patients may have some special vul-
nerability to TB in addition to the use of CSs, sDMARDs
and TNFi; LTBI might even play a role in the onset of
RD [25, 26]. Reactivation of LTBI was estimated to be
the cause of active TB in almost all cases, although only
30% of the patients had at least one reported exposure
to TB. Although the oldest patients were born when pul-
monary TB was common, reported exposure rates were
similar to those in the younger patients. This is perhaps
related to the old stigma of TB, which can make it diffi-
cult for older people to mention their past TB exposures
to medical staff.
We found no evidence of increasing TB incidence
among those with RD. As TB incidence in the population
decreases, the number of exposures also decreases. In
a low-incidence country, the rate of recently acquired
active infections remains low because TB transmission
is rare. In a high-incidence country, we would probably
see more recently acquired TB infections [27].
Given that new medications help to retain functional
capacity, people with RDs may continue working for lon-
ger [1, 28, 29]. In future, potential occupational exposure
requires attention, especially with regard to treatment of
patients with TNFi. People from low-incidence TB coun-
tries may also be exposed to TB when they travel to
high-incidence areas for work or leisure. Physicians
should be aware of the TB risk for immigrants from a
high-incidence area.
An increased risk of TB is reported for those in con-
tact with TB, for patients undergoing dialysis, under-
weight people, patients receiving TNFi, health-care
workers, immigrants from countries with a high burden
of TB, patients with cancer or diabetes, alcohol abusers,
smokers and individuals with radiological findings of fi-
brotic lesions [23, 30, 31]. These risk factors should help
clinicians if they suspect LTBI and active TB.
In some RA patients, previous TB was treated before
effective anti-TB drugs were available. Other reasons for
earlier inadequate TB treatment include side-effects and
resistant strains of M. tuberculosis. Negative TST in five
previously TB-treated RA patients underlines the fact
that TST is not a reliable tool when examining patients
with immunosuppressive diseases or medication.
Therefore, a history of TB and its treatment should gov-
ern treatment decisions in patients with RD.
The most prevalent form of TB in the general popula-
tion is pulmonary, comprising >80% of cases, whereas
disseminated TB is rare (5–10%) [32–35]. RA patients
treated with TNFi may more often present with dissemi-
nated or extra-pulmonary TB [7, 20, 36]. Our RD
patients had a rate of disseminated disease 19.6%, in
agreement with the findings of a Japanese study involv-
ing 20 RA patients [37].
Delayed diagnosis and treatment of TB may lead to
more severe illness and TB transmission. One system-
atic review indicated that the median duration of delay
from symptom onset to treatment initiation ranged from
60 to 90 days [38]. Our mean time from symptom onset
to TB diagnosis was 16 weeks, median 9 weeks. A major
problem is that TB has no specific symptoms and can
be asymptomatic [37]. Active TB infection cannot be
ruled out by normal CRP or ESR. Physicians must be
aware of pulmonary TB whenever a cough lasts
 3 weeks or a patient is coughing up blood or sputum;
it is not unusual, however, for an unsuspicious post-
infectious cough to last for  8 weeks [39]. The diagno-
sis of extra-pulmonary TB is even more challenging.
The most important matter to assess is possible TB
exposure and predisposing factors (age, TNFi, underly-
ing pulmonary or kidney disease, active cancer, current
smoking, heavy drinking and underweight). We identified
only five RA patients without any predisposition to TB;
three of them were born in Finland before 1950, and
FIG. 2 Organ distribution of tuberculosis in rheumatic






















Organ distribution of 
TB in RD patients 
No statistically significant difference appeared in the organ
distribution of TB in patients without bDMARDs and in
patients taking such drugs. bDMARD: biological DMARD;
EPTB: extra-pulmonary tuberculosis; PTB: pulmonary tu-
berculosis; RD: rheumatic disease; TB: tuberculosis.








ap/article-abstract/3/2/rkz020/5542402 by Arts Faculty Library user on 03 D
ecem
ber 2019
one had travelled in a high-incidence country before de-
veloping the disease.
The fatality rate of RA patients with TB was high when
compared with the 3–13% case fatality rate reported by
the World Health Organization as European TB treat-
ment outcome data 1996–2005. This may be associated
with frailty and with polypharmacy issues that compli-
cate the treatment of RA and co-morbidities.
Owing to our heterogeneous RD group, we focused
on the clinical information for patients with RA, a fact
which might limit our study. Our study period might be
also too short to show the effect of bDMARDs on TB
rates, but the incidence trend was still declining. Clinics
may vary in notification rates for clinically diagnosed TB
cases. Unfortunately, our analysis has demanded con-
siderable time, but these data still offer clinically relevant
information on the risk and manifestation of TB among
patients with RD.
Conclusion
The incidence of TB among RD patients was approxi-
mately four times as high as that for latent TB of the gen-
eral population and has declined between 1995 and 2007.
At the time of RD diagnosis, TB exposure and factors
predisposing to TB require close evaluation, and re-
evaluation is advisable when immunosuppression increases,
upon initiation of TNFi therapy, or in the case of new expo-
sure. Systematic testing and treatment of LTBI in popula-
tions at risk is crucial in the prevention of active TB [32].
Although the local incidence of TB may be low, overall
TB should be kept in mind if a patient with a rheumatic
disease presents with otherwise unexplained symptoms
or with radiological findings supporting TB.
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